Literature DB >> 7522964

Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody.

P B Chapman1, S D Gillies, A N Houghton, R M Reilly.   

Abstract

R24, a mouse monoclonal antibody against GD3 ganglioside, exhibits a wide range of in vitro effector functions. It also has the ability to bind to itself, presumably through homophilic Fab-Fab interactions, which have been proposed to contribute to its high relative avidity for GD3 and to its effector function activity. It is not known which of these characteristics is necessary for the antitumor effects observed in melanoma patients treated with R24. A mouse-human chimeric R24 (chR24) molecule has been constructed in which the GD3-binding site is preserved. Chimeric R24 demonstrates a lower level of binding to GD3 than does mouse R24 suggesting that there may be some differences between the GD3-binding sites of the two mAb or that Fc determinants can contribute to R24 avidity for GD3. The property of homophilic binding is retained by chR24, demonstrating formally that homophilic binding of R24 involves interactions between variable domains. Both R24 and chR24 fix human complement and mediate antibody-dependent cellular cytotoxicity although chR24 was slightly less efficient at the latter. Unlike R24, chR24 was not able to inhibit melanoma cell attachment to plastic surfaces and was not able to activate human T lymphocytes. We hypothesize that chR24 does not bind to GD3 with an avidity high enough to mediate these effector functions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7522964     DOI: 10.1007/bf01533387

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  24 in total

1.  Homophilic binding of mouse monoclonal antibodies against GD3 ganglioside.

Authors:  P B Chapman; H Yuasa; A N Houghton
Journal:  J Immunol       Date:  1990-08-01       Impact factor: 5.422

2.  Induction of IgG antibodies against GD3 ganglioside in rabbits by an anti-idiotypic monoclonal antibody.

Authors:  P B Chapman; A N Houghton
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

3.  Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma.

Authors:  D F Bajorin; P B Chapman; G Wong; D G Coit; J Kunicka; J Dimaggio; C Cordon-Cardo; C Urmacher; L Dantes; M A Templeton
Journal:  Cancer Res       Date:  1990-12-01       Impact factor: 12.701

4.  High-level expression of chimeric antibodies using adapted cDNA variable region cassettes.

Authors:  S D Gillies; K M Lo; J Wesolowski
Journal:  J Immunol Methods       Date:  1989-12-20       Impact factor: 2.303

5.  Cooperative binding of two antibodies to independent antigens by an Fc-dependent mechanism.

Authors:  N S Greenspan; D A Dacek; L J Cooper
Journal:  FASEB J       Date:  1989-08       Impact factor: 5.191

6.  Stimulation of T lymphocyte proliferation by monoclonal antibodies against GD3 ganglioside.

Authors:  K Welte; G Miller; P B Chapman; H Yuasa; E Natoli; J E Kunicka; C Cordon-Cardo; C Buhrer; L J Old; A N Houghton
Journal:  J Immunol       Date:  1987-09-15       Impact factor: 5.422

7.  Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells.

Authors:  S Welt; E A Carswell; C W Vogel; H F Oettgen; L J Old
Journal:  Clin Immunol Immunopathol       Date:  1987-11

8.  Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody.

Authors:  B M Mueller; C A Romerdahl; S D Gillies; R A Reisfeld
Journal:  J Immunol       Date:  1990-02-15       Impact factor: 5.422

9.  Interaction of IgG3 anti-streptococcal group A carbohydrate (GAC) antibody with streptococcal group A vaccine: enhancing and inhibiting effects of anti-GAC, anti-isotypic, and anti-idiotypic antibodies.

Authors:  N S Greenspan; W J Monafo; J M Davie
Journal:  J Immunol       Date:  1987-01-01       Impact factor: 5.422

10.  An Arg-Gly-Asp-directed receptor on the surface of human melanoma cells exists in an divalent cation-dependent functional complex with the disialoganglioside GD2.

Authors:  D A Cheresh; R Pytela; M D Pierschbacher; F G Klier; E Ruoslahti; R A Reisfeld
Journal:  J Cell Biol       Date:  1987-09       Impact factor: 10.539

View more
  1 in total

Review 1.  Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives.

Authors:  Nora Berois; Alvaro Pittini; Eduardo Osinaga
Journal:  Cancers (Basel)       Date:  2022-01-27       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.